Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence-Reference-Cited by-同舟云学术

Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence

Published:2014-12-15 Issue:5 Volume:35 Page:1557-1565
ISSN:1478-3223
Container-title:Liver International
language:en
Short-container-title:Liver Int

Author:

González-Colominas Elena¹,Broquetas Teresa²³,Retamero Alexandra¹,García-Retortillo Montserrat²³,Cañete Nuria²³,Coll Susanna²³,Pellicer Rosa¹,Giménez Maria D.²³,Cabrero Beatriz²³,Bory Felipe²,Knobel Hernando³⁴,Salas Esther¹,Solà Ricard²³,Carrión José A.²³

Affiliation:

1. Pharmacy Department; Hospital del Mar. Universitat Autònoma de Barcelona (UAB); Barcelona Spain

2. Liver Section; Gastroenterology Department, Hospital del Mar. Universitat Autònoma de Barcelona (UAB); Barcelona Spain

3. IMIM (Hospital del Mar Medical Research Institute); Barcelona Spain

4. Service of Infectious Diseases; Hospital del Mar. Universitat Autònoma de Barcelona (UAB); Barcelona Spain

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/liv.12729/fullpdf

Reference29 articles.

1. Global epidemiology of hepatitis C virus infection;Shepard;Lancet Infect Dis,2005

2. Telaprevir for previously untreated chronic hepatitis C virus infection;Jacobson;N Engl J Med,2011

3. Boceprevir for untreated chronic HCV genotype 1 infection;Poordad;N Engl J Med,2011

4. Telaprevir for retreatment of HCV infection;Zeuzem;N Engl J Med,2011

5. Boceprevir for previously treated chronic HCV genotype 1 infection;Bacon;N Engl J Med,2011

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmaceutical Approaches for Treatment of Hepatitis C virus;Current Pharmaceutical Design;2020-10-13

2. Breast cancer, placing drug interactions in the spotlight: is polypharmacy the cause of everything?;Clinical and Translational Oncology;2020-05-24

3. A novel molecular mechanism to explain mutations of the HCV protease associated with resistance against covalently bound inhibitors;Virus Research;2019-12

4. Pharmacist engagement within a hepatitis C ambulatory care clinic in the era of a treatment revolution;Journal of the American Pharmacists Association;2016-11

5. Evaluation of Drug-Drug Interactions between Direct-Acting Anti-Hepatitis C Virus Combination Regimens and the HIV-1 Antiretroviral Agents Raltegravir, Tenofovir, Emtricitabine, Efavirenz, and Rilpivirine;Antimicrobial Agents and Chemotherapy;2016-05